Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users

New Zealand Medical Journal

Volumn 113, Issue 1106, 2000, Pages 98-101

  Brunton, Cheryl ^c   Kemp, Robert ^a   Raynel, Pamela ^c   Harte, David ^c   Baker, Michael ^b  

^a Drugs and Health Development Project   (Australia)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; DRUG ABUSE; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; MALE; NEW ZEALAND; STATISTICS; SUBSTANCE ABUSE; VIROLOGY;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INCIDENCE; MALE; NEEDLE SHARING; NEW ZEALAND; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0034708309     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Miller JA, Tobias MI, Woodfield DG. Hepatitis C [letter]. NZ Med J 1991; 104: 20.
2. Woodfield DG, Harness M, Rix-Trott K. Hepatitis C infections in oral and injectable drug users. NZ Med J 1993; 106: 332-4.
3. Robinson GM, Reynolds JN, Robinson BJ. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. NZ Med J 1995; 108: 103-5.
4. Chetwynd J, Brunton C, Blank M et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. NZ Med J 1995; 108: 364-6.
5. Kemp R, Miller J, Lungley S, Baker M. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. NZ Med J 1998; 111: 50-3.
6. Bell J, Batey RG, Farrell GC et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990; 153: 274-6.
7. Hoek van den JAR, Haastrecht van HJA, Goudsmit J et al. Prevalence, incidence and risk factors of hepatitis C virus infection among drug users in Amsterdam. Infect Dis 1990; 162: 823-6.
8. Crofts N, Hopper JL, Bowden DS et al. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159: 237-41.
9. Beek van I, Buckley R, Stewart M et al. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70: 321-4.
10. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. Aust NZ J Public Health 1997; 21: 102-4.
11. Dean AG, Dean JA, Coulombier D et al. Epi Info, Version 6: a word processing, database and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, Georgia, USA; 1994.
12. Lungley S. Intravenous drug use in New Zealand: a base line study of intravenous drug users and the risk of AIDS. Discussion paper 2. Wellington: Department of Health; 1988.
13. Lungley S, Baker M. The needle and syringe exchange scheme in operation: an evaluation of the first year. Wellington: Department of Health; 1990.
14. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotrophic viruses. Am J Public Health 1996; 86: 655-61.
15. Dickson NP, Austin FJ, Paul C et al. HIV surveillance by testing saliva from injecting drug user: a national study in New Zealand. J Epidemiol Community Health 1994, 48: 55-7.
16. Crofts N, Hopper JL, Milner R et al. Blood-borne virus infections among Australian injecting drug users: implications for the spread of HIV. Eur J Epidemiol 1994; 10: 687-94.
17. Anon. Hepatitis C surveillance shows importance of injecting drug use as risk factor. NZ Public Health Report 1997; 4: 12.
18. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.
19. Alter MJ. The detection, transmission and outcome of hepatitis C virus infection. Infect Agents Dis 1993; 2: 155-66.
20. Ross AG, Burt MJ, Jennings LC et al. Treatment of chronic hepatitis with interferon alpha. NZ Med J 1995; 108: 101-3.
21. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
22. Selman JD, Hannifin J, Deering D, Borren P. Delivery of treatment for people with opioid dependence in New Zealand: Options and recommendations. A commissioned paper for the Ministry of Health, New Zealand; September 1996.